Lawyers are currently completing discovery in a group of 15 Bard PowerPort lawsuits, which will then be narrowed down to six potential trial cases by mid-April 2025.
Each of the selected lawsuits involve allegations that the Bard PowerPort system was defectively designed, resulting in life-threatening complications for plaintiffs.
Parties have until the end of January 2025 to finish depositions and fact discovery for potential Bard PowerPort lawsuit bellwether trials.
Inari Medical issued an Urgent Medical Device Labeling Correction last month, which the FDA has declared a Class I medical device recall.
As the federal litigation heads into it's 2nd year, the Court has re-appointed a group of Bard PowerPort lawsuit attorneys to continue serving in leadership positions in the consolidated multidistrict litigation (MDL)
Bellwether claims will be prepared for early trials to help gauge how juries may respond to evidence and testimony that will be repeated throughout more than 300 other Bard Power lawsuits currently pending in the federal court system.
Lawyers for Bard PowerPort plaintiffs and the manufacturers indicate they are working cooperatively to move through the discovery process and to meet a deadline in 2025 to select claims for early bellwether trials.
Researchers indicate polyurethane catheters, such as those used in Bard PowerPort implants, often lead to early device failure and infections.
Judge compared Bard PowerPort lawsuits to IVC filter litigation, where the majority of cases were filed more than 18 months after the claims were consolidated into a MDL
Of the 25 Bard chemo port devices on the market, at least 15 have been identified in lawsuits filed over failures, infections and other complications among individuals who received the implantable port catheter.
